



<i>Name</i>	O11 biomedical GmbH
<i>Address</i>	Schloßparkstraße 93
<i>Postal Code / City</i>	52074 Aachen · Germany
<i>Contact Person</i>	Richard Ramakers
<i>Phone</i>	+31 6 81 13 00 77
<i>E-Mail</i>	ramakers@o11-biomedical.com
<i>Website</i>	www.o11-biomedical.com
<i>Employees</i>	6
<i>Founded</i>	2022

O11 biomedical, a visionary SME born within BioTex at the RWTH Aachen University, aspires to transform the survival rates and quality of life of patients battling hypercapnia. O11 has developed a minimally invasive, complementary therapeutic approach to hypercapnia to meet the needs of patients and healthcare systems alike: RESPILIQ. This groundbreaking innovation offers a solution by utilizing the human intestine as an alternative respiratory organ to effectively lower pCO₂ levels in the blood. By employing extrapulmonary CO₂ elimination via the gut, RESPILIQ allows the lungs to recover without additional damage from aggressive ventilation techniques. RESPILIQ utilizes readily available raw materials, i.e. CO₂ absorbers and polymers, thus leveraging existing medical device value chains and making it accessible on a global scale.